VERAXA Biotech AG
PublicVERAXA Biotech AG is now publicly traded
The data on this page reflects VERAXA Biotech AG's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
M&A
Apr 22, 2025
Est. Valuation at Exit
$1.64B
Total Funding Raised
$256.41M
Company Overview
VERAXA Biotech AG has raised $256.41M. It was founded in 2021.
VERAXA Biotech AG is a biotechnology company that develops next-generation antibody-based cancer therapies, including antibody-drug conjugates (ADCs) and T-cell engagers.
AI Layer
Application
VERAXA Biotech AG Comparables
Compare VERAXA Biotech AG with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| CytomX Therapeutics | 87% | |
| Eli Lilly and Company | 79% | |
| Zymeworks Inc. | 78% |
For institutional investors. Book with your work email.
VERAXA Biotech AG Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| M&A | Apr 22, 2025 | ||||
| Series B | Jun 27, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
VERAXA Biotech AG Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EMBLEM Technology Transfer | M&A, Series B |
| European Molecular Biology Laboratory | M&A, Series B |
| Xlife Sciences AG | M&A, Series B |
| Voyager Acquisition Corp. | M&A |
Recent news
Latest coverage and updates
- is_developingOct 21, 2026
VERAXA Biotech GmbH is developing antibody-based cancer therapies through its BiTAC platform to improve treatment selectivity and potentially reduce toxicity to healthy tissues, with applications in antibody-drug conjugates and T-cell engagers and promising preclinical findings for its lead BiTAC-TCE program reported on Oct 21st '26.
- attends_eventOct 13, 2026
VERAXA Biotech GmbH presents first in vivo proof-of-concept data and additional in vitro findings for its BiTAC-ADC platform at the 17th World ADC Congress in California on Oct 13th '26.
- hiresSep 4, 2026
In Switzerland on Sep 4th '26, VERAXA Biotech GmbH appoints Raju Willener as Chief Financial Officer, effective immediately, to support its oncology pipeline and BiTAC(R) platform.
- is_developingAug 28, 2026
VERAXA Biotech GmbH and Secarna Pharmaceuticals reach an early research milestone as their antibody oligonucleotide conjugate candidate demonstrates greater potency than an unconjugated oligonucleotide in an initial in vitro study for potential autoimmune and chronic immune disease treatments in Switzerland and Germany on Aug 24th '26.
- is_developingAug 27, 2026
In May 2025, VERAXA Biotech GmbH enters a co-discovery alliance with OmniAb to develop a bispecific ADC for solid tumors.
For institutional investors. Book with your work email.
VERAXA Biotech AG Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.